Patricia Inácio, PhD, science writer —

Neuropore Therapies has received a $4.8 million grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop a small molecule that will block the activation of a protein receptor, called toll-like receptor 2 (TLR2), that fuels inflammation in people with Parkinson’s disease. The grant will support…

Lucy Therapeutics (LucyTx) has received a $4.9 million, two-year grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance work in the company’s mitochondrial platform that could lead to new Parkinson’s disease treatments. The award includes access to a network of MJFF staff and relevant foundation…

The Michael J. Fox Foundation (MJFF) has named Brit Mollenhauer, MD, a foundation scientific advisor, as the winner of this year’s J. William Langston Award in recognition of her contributions to Parkinson’s research in expanding avenues to new treatments. Mollenhauer’s work has focused on developing…

Practicing tai chi for a year improved gait and balance in early-stage Parkinson’s disease patients, improving both inflammation and metabolism as well as brain function, according to a recent study. The study, “Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients,” was published…

Scientists have created a set of sensors that can help measure muscle strain and bulging while integrated in a wearable device, such as clothes, a feature that may be of use for people with Parkinson’s disease. The sensors could be used to remotely monitor disease progression, quantify the effects, and…

Using Cerevance’s oral CVN424 as an add-on therapy for Parkinson’s motor symptoms led to a significant and meaningful dose-dependent reduction in “off” time — periods when symptoms reappear or worsen — data from a Phase 2 study show. The trial also met its safety objectives, according to a…

Vyant Bio and OrganoTherapeutics are teaming up to speed the discovery of new candidates for treating Parkinson’s disease. The collaboration will leverage OrganoTherapeutic’s patient-derived “mini-brains” — midbrain organoids — derived from induced pluripotent stem cells (iPSCs) and Vyant Bio’s expertise in machine learning technology to identify new…

The first patient has been dosed in a Phase 3 trial testing GE Healthcare’s new dopamine transporter positron emission tomography (PET) tracer, which is designed to aid in the evaluation of adults with suspected parkinsonian syndromes, including Parkinson’s disease. The PET agent is a…

IMAC Holdings has started dosing the third and final group of participants in a Phase 1 clinical trial assessing the potential of its umbilical cord-derived stem cell therapy for treating bradykinesia, an early motor symptom of Parkinson’s disease characterized by slowness or difficulty in movement. The open-label trial…

A positron emission tomography (PET) tracer for the alpha-synuclein protein, whose damaging clumps mark Parkinson’s, captured its toxic aggregates in a living brain for a first time — instead of in post-mortem tissue as is done to date, scientists reported. The tracer, called ACI-12589, is a diagnostic tool designed to…